Vnitr Lek 2023, 69(2):128-131 | DOI: 10.36290/vnl.2023.020

Levothyroxine suppressive therapy in differentiated thyroid cancer treatment

Jan Drugda1, Jan Čáp1, Mikuláš Kosák2, Filip Gabalec1
1 Fakultní nemocnice Hradec Králové a Univerzita Karlova, Lékařská fakulta v Hradci Králové
2 Ústřední vojenská nemocnice - Vojenská fakultní nemocnice Praha

Levothyroxine therapy in management of diferentiated thyroid carcinoma (DTC) has been common practice for decades. Levothyroxine is being administered to patiens with DTC after total thyreoidectomy (with or without postopreative radioiodine treatment) not only to restore euthyroidism but to suppress the production of thyroid-stimulating hormone (TSH) as well because TSH is considered as a growth factor for thyroid follicular cells. However there has been a downside to this threatment recently. The main concerns are the known risks related to iatrogenic subclinical or even mild but clinicaly overt iatrogenic hyperthyroidism. Therefore individualized treatment approach aiming to balance between the risk of tumor recurence and the risks related to hypertyhroidism in view of pateints age, risk factors and comorbidities is essential. Close folow-up is therefore necessary with frequent dose adjustments according to target TSH values published in American Thyroid Association guidelines.

Keywords: thyroid, differentiated thyroid cancer, levothyroxine, TSH suppression.

Accepted: March 23, 2023; Published: March 30, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Drugda J, Čáp J, Kosák M, Gabalec F. Levothyroxine suppressive therapy in differentiated thyroid cancer treatment. Vnitr Lek. 2023;69(2):128-131. doi: 10.36290/vnl.2023.020.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kimura T, Van Keymeulen A, Golstein J, et al. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev. 2001;22(5):631-56. Available from: DOI:. Go to original source...
    2. Haugen BR, Alexander EK, Bible KC, et al. 2015 AmericanThyroidAssociation Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. Available from: DOI:. Go to original source... Go to PubMed...
    3. Bruno R, Ferretti E, Tosi E, et al. Modulation of thyroid‑specific gene expression in normal and nodular human thyroid tissues from adults: an in vivo effect of thyrotropin. J. Clin. Endocrinol. Metab. 2005;90(10):5692-7. Available from: DOI:. Go to original source...
    4. Biondi B, Filetti S, Schlumberger M. Thyroid‑hormone therapy and thyroid cancer: a reassessment. Nat. Clin. Pr. Endocrinol.Metab. 2005;1(1):32-40. Available from: DOI:. Go to original source...
    5. Ferrari SM, Fallahi P, Elia G, et al. Thyroid autoimmune disorders and cancer. Seminars in Cancer Biology 2020;64:135-146. Available from: DOI:. Go to original source...
    6. Boelaert K, Horacek J, Holder RL, et al. Serum Thyrotropin Concentration as a Novel Predictor of Malignancy in Thyroid Nodules Investigated by Fine‑Needle Aspiration. J Clin Endocrinol Metab. 2006;91(11):4295-301. Available from: DOI:< https://doi.org/10.1210/jc.2006-0527>. Go to original source... Go to PubMed...
    7. Soh EY, Sobhi SA, Wong MG, et al. Thyroid‑stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines. Surgery. 1996;120(6):944-7. Available from: DOI:. Go to original source... Go to PubMed...
    8. McGriff NJ, Csako G, Gourgiotis L, et al. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med. 2002;34(7-8):554-64. Available from: DOI:. Go to original source...
    9. Sugitani I, Fujimoto Y, Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial. J Clin Endocrinol Metab. 2010;95(10):4576-83. Available from: DOI:. Go to original source...
    10. Klubo‑Gwiezdzinska J, Auh S, Gershengorn M, et al. Association of thyrotropin suppression with survival outcomes in patients with intermediate - and high‑risk differentiated thyroid cancer. JAMA Netw Open. 2019;2(2):e187754. Available from: DOI:. Go to original source... Go to PubMed...
    11. Cooper DS, Specker B, Ho M, et al. Thyrotropins uppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid. 1998;8(9):737-44. Available from: DOI:< http://doi.org/10.1089/thy.1998. 8. 737>. Go to original source... Go to PubMed...
    12. Diessl S, Holzberger B, Mader U, et al. Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 2012;76(4):586-92. Available from: DOI:. Go to original source...
    13. Ito Y, Masuoka H, Fukushima M, et al. Prognosis and prognostic factors of patients with papillary carcinoma showing distant metastasis at surgery (M1 patients) in Japan. Endocr J. 2010;57(6):523-31. Available from: DOI:. Go to original source... Go to PubMed...
    14. Shargorodsky M, Serov S, Gavish D, et al. Long‑term thyrotropin‑suppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma. Thyroid. 2006 Apr;16(4):381-6. Available from: DOI:. Go to original source... Go to PubMed...
    15. Biondi B, Fazio S, Cuocolo A, et al. Impaired cardiac reserve and exercise capacity in patients receiving long‑term thyrotropin suppressive therapy with levothyroxine. J Clin Endocrinol Metab. 1996;81(12):4224-8. Available from: DOI:< https://doi.org/10.1210/jcem.81. 12. 8954019>. Go to original source...
    16. Watanabe H, Ma M, Washizuka T, et al. Thyroid hormone regulates mRNA expression and currents of ion channels in rat atrium. Biochem Biophys Res Commun. 2003 Aug 29;308(3):439-44. Available from: DOI:. Go to original source...
    17. Auer J, Scheibner P, Mische T, et al. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. AmHeart J. 2001;142(5):838-42. Available from: DOI: . Go to original source...
    18. Brancatella A, Marcocci C. TSH suppressive therapy and bone. Endocr Connect. 2020;9(7):R158-R172. Available from: DOI: . Go to original source... Go to PubMed...
    19. Yoon BH, Lee Y, Oh HJ, et al. Influence of Thyroid‑stimulating Hormone Suppression Therapy on Bone Mineral Density in Patients with Differentiated Thyroid Cancer: A Meta‑analysis. J Bone Metab. 2019;26(1):51-60. Available from: DOI:. Go to original source...
    20. Tagay S, Herpertz S, Langkafel M, et al. Health‑related quality of life, anxiety and depression in thyroid cancer patients under short‑term hypothyroidism and TSH‑suppressive levothyroxine treatment. Eur J Endocrinol. 2005;153(6):755-63. Available from: DOI:. Go to original source...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.